Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Bahr

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Maryland Medical Journal (Baltimore, Md. : 1985)|October 1, 1992
Papillary muscle rupture: a reversible cause of cardiogenic shockE Chwa, A Gonzalez, R D Bahr, et al.
Cardiology|August 7, 1998
Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet SubstudyV L Serebruany, R D Bahr, C M O'Connor, et al.
American Heart Journal|January 29, 2000
Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency departmentP A Gurbel, D J Kereiakes, M R Dalesandro, et al.
Journal of the American College of Cardiology|June 17, 1998
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary ArteriesP A Gurbel, V L Serebruany, A R Shustov, et al.
Cardiology|July 15, 2000
Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we?G V Nair, P A Gurbel, S Y Fuzaylov, et al.
Coronary Artery Disease|November 21, 1998
Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysisP A Gurbel, V L Serebruany, A R Shustov, et al.
The American Journal of Cardiology|December 15, 1991
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study GroupJ M Kirshenbaum, R D Bahr, J T Flaherty, et al.
Stroke|January 28, 1998
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III InvestigatorsV L Serebruany, P A Gurbel, A R Shustov, et al.
The New England Journal of Medicine|December 24, 1987
A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplastyA D Guerci, G Gerstenblith, J A Brinker, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Maryland Medical Journal (Baltimore, Md. : 1985)|October 1, 1992
Papillary muscle rupture: a reversible cause of cardiogenic shockE Chwa, A Gonzalez, R D Bahr, et al.
Cardiology|August 7, 1998
Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet SubstudyV L Serebruany, R D Bahr, C M O'Connor, et al.
American Heart Journal|January 29, 2000
Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency departmentP A Gurbel, D J Kereiakes, M R Dalesandro, et al.
Journal of the American College of Cardiology|June 17, 1998
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary ArteriesP A Gurbel, V L Serebruany, A R Shustov, et al.
Cardiology|July 15, 2000
Combining necrosis and platelet markers for perfecting myocardial infarction rule out: how close are we?G V Nair, P A Gurbel, S Y Fuzaylov, et al.
Coronary Artery Disease|November 21, 1998
Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysisP A Gurbel, V L Serebruany, A R Shustov, et al.
The American Journal of Cardiology|December 15, 1991
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study GroupJ M Kirshenbaum, R D Bahr, J T Flaherty, et al.
Stroke|January 28, 1998
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III InvestigatorsV L Serebruany, P A Gurbel, A R Shustov, et al.
The New England Journal of Medicine|December 24, 1987
A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplastyA D Guerci, G Gerstenblith, J A Brinker, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 4